Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer

Pelareorep is a novel immunotherapeutic agent being developed by Oncolytics Biotech Inc. to treat advanced or metastatic breast cancer. Results from the BRACELET-1 study showed pelareorep-based therapy significantly improved progression-free survival and overall survival compared to standard chemotherapy alone in this patient population. Oncolytics plans to conduct a larger registration-enabling study of pelareorep in metastatic breast cancer, as well as evaluate its potential to reduce the risk of disease recurrence in earlier-stage patients. The expert highlighted the unmet need for additional treatment options for breast cancer, especially for patients who progress on existing therapies.